Swarthmore Group Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1,124.5% during the first quarter, Holdings Channel reports. The fund owned 25,090 shares of the medical research company’s stock after acquiring an additional 23,041 shares during the quarter. Thermo Fisher Scientific makes up 3.1% of Swarthmore Group Inc.’s holdings, making the stock its 6th largest holding. Swarthmore Group Inc.’s holdings in Thermo Fisher Scientific were worth $11,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Annapolis Financial Services LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $26,000. ShoreHaven Wealth Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. Larson Financial Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 38.5% during the 4th quarter. Larson Financial Group LLC now owns 72 shares of the medical research company’s stock worth $34,000 after buying an additional 20 shares during the period. Oder Investment Management LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $34,000. Finally, ADE LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $40,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.
A number of equities research analysts recently issued reports on TMO shares. BTIG Research increased their target price on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. SVB Leerink increased their price objective on shares of Thermo Fisher Scientific from $525.00 to $560.00 and gave the stock an “outperform” rating in a report on Tuesday, February 2nd. KeyCorp raised shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 price objective on the stock in a report on Wednesday, March 24th. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a report on Monday, March 29th. Finally, Credit Suisse Group raised their target price on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a research note on Tuesday, January 12th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $534.45.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, April 29th. The medical research company reported $7.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $6.69 by $0.52. The business had revenue of $9.91 billion for the quarter, compared to the consensus estimate of $9.69 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The firm’s revenue for the quarter was up 59.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.94 earnings per share. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 16th. Stockholders of record on Tuesday, March 16th were paid a $0.26 dividend. The ex-dividend date was Monday, March 15th. This represents a $1.04 annualized dividend and a dividend yield of 0.22%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. Thermo Fisher Scientific’s dividend payout ratio is currently 8.42%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also: What does a bar chart display?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.